SEC Form 4 · accession 0000899243-17-011489
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard L Love
Director
Period of report
Apr 29, 2017
Accepted (ET)
May 2, 2017 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 29, 2017 | M | 34,736 | — | A | 88,318 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2,F3 | — | Apr 29, 2017 | M | 34,736 | D | — | — | Common Stock | 34,736 | 0 | D |
Explanation of responses
- F1CTIC completed a 1-for-10 reverse stock split in January 2017. All share amounts reported in this Form 4 have been retroactively adjusted to reflect this stock split.
- F2Each restricted stock unit represents the right to receive, at settlement, one share of CTIC common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
- F3This restricted stock unit was granted on April 29, 2016 and vested on April 29, 2017.
Remarks
Exhibit List: Exhibit 24 -- Power of Attorney